Soma Miho, Hirata Akira, Takahashi Takamitsu, Okinami Satoshi
Department of Ophthalmology, Saga University Faculty of Medicine, Saga, Japan.
Case Rep Ophthalmol. 2011 Jan 7;2(1):5-9. doi: 10.1159/000323472.
A 60-year-old woman, who had been diagnosed with and treated for Vogt-Koyanagi-Harada (VKH) disease 17 years before, was receiving pegylated interferon-? and ribavirin therapy for chronic hepatitis C virus. Three weeks after the start of therapy, she complained of visual blurring, eye pain, and an increased hearing loss. Based on a slit lamp and fundus examination, she was diagnosed with a relapse of VKH disease. After discontinuation of the pegylated interferon-α and ribavirin therapy and administration of corticosteroid therapy, her visual acuity returned to 1.0 in both eyes without ocular inflammation, and remained stable thereafter. When interferon therapy is administered to hepatitis C virus patients, those who also have a history of VKH disease must be closely monitored for ophthalmologic complications.
一名60岁女性，17年前曾被诊断为Vogt-小柳-原田（VKH）病并接受过治疗，目前正在接受聚乙二醇化干扰素-α和利巴韦林治疗慢性丙型肝炎病毒。治疗开始三周后，她出现视力模糊、眼痛和听力损失加重。根据裂隙灯和眼底检查，她被诊断为VKH病复发。停用聚乙二醇化干扰素-α和利巴韦林治疗并给予皮质类固醇治疗后，她的双眼视力恢复到1.0，无眼部炎症，此后保持稳定。当对丙型肝炎病毒患者进行干扰素治疗时，有VKH病史的患者必须密切监测眼科并发症。
